GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- A5970 IrbesartanTarget: Angiotensin AT1 ReceptorsSummary: Angiotensin II inhibitor
- A1435 CP-945598 HClSummary: CB1 antagonist,selective and high affinity
- A1709 GW9508Target: Free Fatty Acid ReceptorsSummary: FFA1/GPR40 agonist,potent and selective
- A2025 Plerixafor (AMD3100)2 CitationSummary: CXCR4 chemokine receptor antagonist
- A1929 MacitentanSummary: Endothelin (ET)(A) and ET(B) receptor antagonist
- A2547 Vortioxetine (Lu AA21004) HBrSummary: 5-HT receptor modulator, antidepressant and anxiolytic
- A2098 PRX-08066 Maleic acidSummary: 5-HT2B receptor antagonist,potent and selective
- A8339 TAK-875Target: GPR40Summary: GPR40 agonist
- A8439 GSK1292263Summary: Novel GPR119 agonist
- A8454 Istradefylline (KW-6002)Target: Adenosine A2A ReceptorsSummary: Selective A2A receptor antagonist